
Although widely reported to affect older adults more, coronavirus disease 2019 (COVID-19) also affects adolescents, especially those with co-morbidities, including heart diseases. The safety and efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines have been established in healthy adolescents. Yet, there are data for humoral and cellular immunogenicity in adolescents with cardiac diseases. Neutralizing antibodies and cellular immunity were absent in four of the eight post-HTx patients and one with single ventricle CHD. The SARS-CoV-2 mRNA vaccine has efficient immunogenicity for adolescents with CHD, IPAH, and DCM. However, half of the post-HTx patients could not acquire sufficient humoral immunity.
Like
Save
Share